ALLERGY THERAPEUTICS PLC

Regulatory Filings • Jul 24, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1566N

Allergy Therapeutics PLC

24 July 2014

24 July 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of Results and Trading Update

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today provides a trading update for the year to 30 June 2014 ahead of its preliminary results to be announced on 22 September 2014.

The Company reports that it expects revenues, before milestones and rebates, of approximately £45.7m (2013: £39.9m), an increase of 14% on the previous year and marginally ahead of market expectations.  This double digit sales growth has been driven by the Company's improving trading performance as it continues to increase its market share in all of its main markets and supported by a foreign exchange benefit of £2.3m.

Manuel Llobet, Chief Executive Officer, commented as follows:-

"Along with resuming our plans for Pollinex Quattro in the US, strengthening our position in Europe has been a top management priority.  Our focus on ultra-short, aluminium free, subcutaneous allergy vaccines is driving consistent growth across all our key European markets.  The strong financial performance demonstrates that we are building a sound, attractive business in Europe that will be the platform for our expansion globally."

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel / Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell / Mo Noonan

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving revenues in the prior financial year of £39.3 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORBUGDRXXDBGSX